SEC
SWTX

Seven Eight Capital’s SpringWorks Therapeutics SWTX Stock Holding History

Seven Eight Capital’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-56,777
Closed -$1.82M – 567
2024
Q3 		$1.82M Buy
56,777
+7,553
+15% +$282K 0.16% 211
2024
Q2 		$1.85M Buy
+49,224
New +$2.07M 0.19% 156
2024
Q1 		– Sell
-42,303
Closed -$1.54M – 812
2023
Q4 		$1.54M Buy
+42,303
New +$1.1M 0.18% 170

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Seven Eight Capital's SWTX Position: Q4 2024 in Review

Seven Eight Capital sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 56,777 shares — an estimated $1.82M sold.

Seven Eight Capital first reported a position in SWTX in Q4 2023 and held it in 3 quarters. The position peaked at $1.85M in Q2 2024. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

  • Seven Eight Capital reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Seven Eight Capital sold 56,777 SpringWorks Therapeutics shares in Q4 2024, an estimated $1.82M.
  • Seven Eight Capital first reported a position in SpringWorks Therapeutics in Q4 2023 and held it in 3 quarters.
  • Seven Eight Capital's SpringWorks Therapeutics position peaked at $1.85M in Q2 2024.
  • 216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on Seven Eight Capital's 13F filing for Q4 2024.